Association between ABO blood groups and hematological myeloid neoplasms in adolescents and adults

Miao Zhou, Tongyu Li, Yongcheng Sun, Guifang Ouyang, Wanchuan Zhuang, Ping ZhangFrontiers in Medicine 2024 · DOI

TL;DR

A retrospective study of 792 patients suggests that ABO blood groups may influence the risk of developing hematological myeloid neoplasms. Specifically, individuals with blood type A showed a significantly higher prevalence of these bone marrow cancers, while blood type AB appeared to have a protective effect, appearing much less frequently in the patient cohort than in the general population.

What Problem Does This Paper Address?

Hematological myeloid neoplasms—a group of cancers originating in the bone marrow, including Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)—often appear with "obscure" risk factors. Unlike some solid tumors where environmental or genetic links are well-mapped, the epidemiological drivers for these blood cancers remain under-explored in adults.

While previous research has hinted at a link between ABO blood types and various malignancies (like pancreatic or gastric cancers), studies focusing on myeloid neoplasms have been scarce and often limited to pediatric populations. This paper seeks to fill that gap by investigating whether the specific sugars (antigens) on the surface of our red blood cells correlate with the incidence of these diseases in adolescents and adults.

Methods

The researchers conducted a retrospective clinical study at the First Affiliated Hospital of Ningbo University, covering a six-year period (2017–2023).

  • Cohort Selection: They initially identified 1,022 cases but applied rigorous exclusion criteria to remove "noise." They excluded patients with conditions already known to correlate with blood types (e.g., Type 2 diabetes, hepatitis B, or cardiovascular diseases) to ensure the results specifically reflected the cancer risk. This left 792 eligible cases.
  • Classification: Patients were categorized into four groups based on the 2016 WHO classification: AML, CML (Chronic Myeloid Leukemia), MDS, and MPN (Myeloproliferative Neoplasms).
  • Statistical Rigor: To compare the patient data against the general population, the team used the Chi-square test and applied the Bonferroni correction. This is a standard but vital statistical adjustment used when performing multiple comparisons to reduce the likelihood of "false positives" (Type I errors).

Datasets

  • Study Group: A clinical dataset of 792 adolescent and adult patients (463 male, 329 female) from the First Affiliated Hospital of Ningbo University.
  • Control Group: Because the hospital lacked a dedicated internal control group for blood type distribution, the authors utilized a massive 2018 census study (Liu et al.). This reference dataset included 3,827,125 Chinese adults from the National Free Pre-conception Health Examination Project (NFPHE), providing a robust baseline for the expected blood type distribution in the Han Chinese population.

Key Insights and Ideas

  • The "A" Risk Factor: Blood type A was significantly overrepresented in patients with AML and MDS. The authors hypothesize this might be due to "molecular mimicry." Some tumor cells express "A-like" antigens; in individuals who already have type A blood, the immune system may fail to recognize these cancerous cells as foreign, allowing them to evade surveillance.
  • The "AB" Shield: Across all four disease categories, blood type AB was significantly less common than expected. This suggests a potential protective effect, though the biological mechanism for why the combination of A and B antigens might be protective remains a subject for future inquiry.
  • Beyond Transfusions: The paper reinforces the idea that the ABO system isn't just a hurdle for blood transfusions. Because these antigens are glycosyltransferases (enzymes that modify carbohydrates on cell surfaces), they likely play a role in cell signaling, adhesion, and how tumors interact with their microenvironment.

Key Results

The study found distinct shifts in blood type prevalence among cancer patients compared to the 30.54% (Type A) and 9.66% (Type AB) benchmarks in the control population:

  • AML Patients: Type A prevalence jumped to 41.52%, while Type AB plummeted to 4.39% ($P_c < 0.05$).
  • MDS Patients: Type A was even higher at 45.10%, with Type AB dropping to 2.94% ($P_c < 0.05$).
  • MPN Patients: While other types were stable, Type AB was nearly non-existent at only 1.01%.
  • CML Patients: Showed a significant decrease in Type AB (3.4%), but the increase in Type A was not statistically significant after the Bonferroni correction.

Limitations and Future Work

The authors are transparent about several hurdles:

  • Population Specificity: The study focused almost exclusively on Han Chinese patients, meaning the results might not generalize to other ethnic groups with different baseline blood type distributions.
  • Age Mismatch: The control group (ages 21–49) was younger than the study's median patient age (63), which could introduce subtle demographic biases.
  • Confounding Infections: Factors like Helicobacter pylori infection, which is linked to both blood type and certain cancers, were not screened for in this cohort and could potentially interfere with the results.

The paper concludes that while the association is clear, the "why" remains elusive. Future research needs to move into the lab to perform molecular mechanistic investigations to see exactly how these blood group antigens influence the "birth" and progression of myeloid leukemia cells.

Summary updated

Abstract

The study suggests a potential association between ABO blood types and the risk of developing hematological myeloid neoplasms in adolescents and adults. Further research is warranted to elucidate the underlying mechanisms of this relationship.
BibTeX
@inproceedings{zhou2024association,
  author = {Miao Zhou and Tongyu Li and Yongcheng Sun and Guifang Ouyang and Wanchuan Zhuang and Ping Zhang},
  title = {{Association between ABO blood groups and hematological myeloid neoplasms in adolescents and adults}},
  booktitle = {Frontiers in Medicine},
  year = {2024},
  doi = {10.3389/fmed.2024.1456695},
}
Figure